Firstly, resistance to Glofitamab is linked to the downregulation of p53 targets and the overexpression of MYC ones, while increased frequency of TP53 mutations was identified in patients with DLBCL progression [81,92]. Here, MYC is linked to diffuse large B-cell lymphoma.